A Goal of Relief for Those with Chronic Pain


(DGIwire) — The World Cup riles up sports fans on every continent. Even for people who don’t typically enjoy watching sports, the World Cup became more of a community event, with people gathering at friends’ houses or local bars to cheer on their favorite teams. Much like the Super Bowl and World Series, watching the World Cup brings people together for some friendly competition. However, for people suffering from chronic pain, simply sitting and watching such energy-charged games can be too much to bear.

The National Library of Medicine defines chronic pain as any pain that lasts more than 12 weeks. Some of the most common manifestations of chronic pain include back pain, migraines and joint pain. Sometimes it can arise from a specific injury, a long-term illness or emotional distress. Other health problems—such as sleep disturbances, decreased appetite and fatigue—usually accompany chronic pain, adding to the patient’s discomfort.

Fortunately, BioDelivery Sciences International (BDSI), a specialty pharmaceutical company, has dedicated its time and research to finding an effective delivery system for an opioid for the treatment of moderate to severe chronic pain, called BEMA® Buprenorphine.

BEMA Buprenorphine is currently in late-stage clinical development, and the company and its commercial partner Endo Pharmaceuticals recently announced positive top-line results from a pivotal Phase III efficacy study of the drug in opioid-experienced patients. The active agent, buprenorphine, is a partial mu-opioid receptor agonist and kappa antagonist, making it different from full mu-opioid agonists such as morphine. Buprenorphine is classified as a Schedule III controlled substance, meaning it has a lower abuse and addiction potential than Schedule II drugs.

Dr. Mark A. Sirgo, President and CEO of BDSI, says, “Our goal as a company is to develop innovative ways to deliver effective treatments and to address the problem of opioid abuse.   We are doing this both through the development of a product for the treatment of opioid dependence and through the development of pain treatments that may have a lower potential for abuse.”

Copyright-free content by DGIwire.